Eli Lilly & Co. vs. Tempest Therapeutics, Inc. Common Stock
Tempest Therapeutics, Inc. Common Stock (TPST) comes out ahead, leading on 3 of 5 compared factors.
Size & Scale
| LLY | TPST | |
|---|---|---|
| Market Cap | $1.05 trillion | $17.53 million |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | $-40,472,000 |
LLY leads on 2 of 2 size & scale factors.
Valuation
| LLY | TPST | |
|---|---|---|
| P/E Ratio | 39.43 | — |
| Price / Book | 30.90 | -16.08 |
| Price / Sales | 13.14 | — |
TPST leads on 1 of 1 valuation factors.
Profitability
| LLY | TPST | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | 3713.03% |
TPST leads on 1 of 1 profitability factors.
Dividend
| LLY | TPST | |
|---|---|---|
| Dividend Yield | 0.59% | — |
| Payout Ratio | 23.23 | — |
LLY and TPST split the dividend factors evenly.
Risk & Sentiment
| LLY | TPST | |
|---|---|---|
| Short Interest | 1.29% | 1.07% |
TPST leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, TPST overview, TPST financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.